Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy

Preliminary data of an open-label study

Loredana Dinapoli, Marta Maschio, Bruno Jandolo, Alessandra Fabi, Andrea Pace, Francesca Sperati, Paola Muti

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

Original languageEnglish
Pages (from-to)353-359
Number of pages7
JournalNeurological Sciences
Volume30
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

etiracetam
Brain Neoplasms
Epilepsy
Seizures
Quality of Life
Karnofsky Performance Status
Anticonvulsants

Keywords

  • Brain tumor-related epilepsy
  • Efficacy
  • Levetiracetam
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy : Preliminary data of an open-label study. / Dinapoli, Loredana; Maschio, Marta; Jandolo, Bruno; Fabi, Alessandra; Pace, Andrea; Sperati, Francesca; Muti, Paola.

In: Neurological Sciences, Vol. 30, No. 4, 2009, p. 353-359.

Research output: Contribution to journalArticle

@article{0bf41173510243889fce2be614275d1e,
title = "Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: Preliminary data of an open-label study",
abstract = "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9{\%}), 2 (11.1{\%}) had reduction in seizure frequency >50{\%}. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.",
keywords = "Brain tumor-related epilepsy, Efficacy, Levetiracetam, Quality of life",
author = "Loredana Dinapoli and Marta Maschio and Bruno Jandolo and Alessandra Fabi and Andrea Pace and Francesca Sperati and Paola Muti",
year = "2009",
doi = "10.1007/s10072-009-0087-x",
language = "English",
volume = "30",
pages = "353--359",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "4",

}

TY - JOUR

T1 - Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy

T2 - Preliminary data of an open-label study

AU - Dinapoli, Loredana

AU - Maschio, Marta

AU - Jandolo, Bruno

AU - Fabi, Alessandra

AU - Pace, Andrea

AU - Sperati, Francesca

AU - Muti, Paola

PY - 2009

Y1 - 2009

N2 - The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

AB - The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

KW - Brain tumor-related epilepsy

KW - Efficacy

KW - Levetiracetam

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=67650815220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650815220&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0087-x

DO - 10.1007/s10072-009-0087-x

M3 - Article

VL - 30

SP - 353

EP - 359

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 4

ER -